Press Releases

2019

Allegro Ophthalmics to Present Clinical Research on the Company’s Novel Integrin-Regulating Portfolio at the American Academy of Ophthalmology Annual Meeting
October 8, 2019

Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Congress and The Retina Society 2019 Annual Meeting
September 3, 2019

Allegro Ophthalmics to Present for the First Time the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the ASRS Annual Meeting 2019
July 24, 2019

Allegro Ophthalmics Announces Positive Topline Vision Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry Age-Related Macular Degeneration
June 4, 2019

Allegro Ophthalmics Announces Positive Results of Ex-U.S. Proof-of-Concept Trial with Integrin Inhibitor ALG-1007 for Dry Eye Disease
May 14, 2019

Allegro Ophthalmics to Present the Results of Its ALG-1007 Ex-U.S. Trial for Dry Eye Disease at the 2019 ASCRS•ASOA Annual Meeting
April 30, 2019

Allegro Ophthalmics Expands Its Anti-Integrin Portfolio with New Front-of-the-Eye Drug Candidate ALG-1007 for the Treatment of Dry Eye Disease
April 25, 2019

Allegro Ophthalmics Appoints Marc Carlson and Rebecca Colbert to the Company’s Board of Directors
April 9, 2019

View prior press releases